Professional Documents
Culture Documents
Breast Cancer Awareness
Breast Cancer Awareness
3. Case Presentation once daily. However, the patient was presented with palpitate,
flustered one week later and evaluated with grade 3 Trigeminy
A 42-year-old non-smoking male came to the hospital with Premature Ventricular Beat Common Terminology Criteria for
cough and sputum for one month. Computed Tomography Adverse Events (CTCAE4.03) (Figure1A, B). Holter showed the
(CT) showed primary tumor located at lower lobe of right lung mean ventricular rate was 83 (62-134) and total frequent ven-
with lymph node metastases in mediastinum and bone metas- tricular premature beat was 17554.He was treated with Meto-
tasis. A CT-guided biopsy of the right lung nodule was per- prolol and obtained response.
formed and showed lungadenocarcinoma.The patient tested
positive for EGFR exon 19del mutation by next-generation
sequencing(NGS, Borning Rock, Guangzhou, China), and he
began undergoing erlotininb 150 mg orally three times daily.
After 10 months, he was assessed as having progressive disease.
After rebiopsy of the left lung nodule, adenocarcinoma was
identified. Next-generation sequencing established a change in
mutation type to EGFR exon 19del and EGFR exon20T790M.
The patient’s treatment was changed toosimertinib 80 mgorally
Figure 1: ECG of the patient. Panel A was before osimertinib, Panel B was after
osimertinib. Rad arrowsshow the large QRS. The speed and voltage was descripting
in the left corner.
*Corresponding Author (s): Yongchang Zhang, Department of medical oncology,
lung cancer and gastrointestinal unit, Hunan cancer hospital/The Affiliated Cancer
Hospital of Xiangya School of Medicine, Changsha, China, Tel:+8613873123436;
Fax:+86073189762327; E-mail: zhangyongchang@csu.edu.cn
Citation: Nong Yang and Yongchang Zhang, Trigeminy Premature Ventricular Beatrelated to Osimertinib
for an EGFR Exon19del Mutation Lung Adenocarcinoma Clinics of Oncology. 2018; 1(4): 1-2.
United Prime Publications: http://unitedprimepub.com
Volume 1 Issue 4-2018 Case Presentation
4. Discussion References
In the report on FLAURA, Tony and Rama lingam reported osi- 1. Mok TS, Wu V, Ahn MJ. Osimertinib or Platinum-Pemetrexed in
mertinib showed superior efficacy and well-tolerant compared EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376(7): 629-
with standard EGFR-TKIs [1,2]. Until now, there were no data 640.
about premature ventricular beat (PVB)related with osimertinib,
2. Soria JC, Ohe Y, Vansteenkiste J. Osimertinib in Untreated EGFR-
except for 10% prolonged QT interval on electrocardiograph
Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;
(ECG) for any grade. Premature ventricular beat, often been
378(2): 113-125.
neglected, was associated with troublesome symptoms [3], es-
pecially with cardiovascular disease [4]. However, in our site, 3. Yusuf S, Camm AJ. The sinus tachycardias. Nat Clin Pract Cardiovasc
among 11 patients received osimertinib, one patient was diag- Med. 2005; 2(1): 44-52.
nosed with grade 3premature ventricular beat. We firstly reported
4. Narichania AD, Schleifer JW, Shen WK. Managing the patient with
a lung adenocarcinoma diagnosed with PVB and presented pal-
episodic sinus tachycardia and orthostatic intolerance. Cardiol J. 2014;
pitate after receiving osimertinib for one week without history of
21(6): 665-73.
cardiovascular disease. After treated with metoprolol, response
was obtained for this patient. 5. Latchamsetty R, Bogun F. Premature Ventricular Complex Ablation in
Structural Heart Disease. Card Electrophysiol Clin. 2017; 9(1): 133-140.
Frequent premature ventricular beat was a highly severe com-
plication of drug administration which may be potentially life-
threating if unrecognized and/or misdiagnosed [5]. Although
uncommon, it may lead to ventricular arrhythmia, evenas ven-
tricular tachycardia or ventricular fibrillation. Hence, an in-
creased awareness among oncologists could allow for early
recognition and appropriate management of osimertinibinduced
trigeminypremature ventricular beat. Suitable intervene should
be added for such patients to avoid side effect related treatment
failure.
5. Ethics
The patient signed and provided written informed consent for the
publication of this case report.
6. Acknowledgment
Copyright ©2018 Yongchang Zhang et all This is an open access article distributed under the terms of the Creative Commons Attribution
License, which permits unrestricted use, distribution, and build upon your work non-commercially. 2